Oral IL-23 Inhibitors

Mechanism

Also known as: oral IL-23 inhibitors

Related News

AbbVie Advances Immunology Pipeline with Skyrizi, Rinvoq, and Lutikizumab Data Expected in 2026

Mar 18, 2026

AbbVie reported positive Phase 3 data for Skyrizi's subcutaneous Crohn's disease treatment and is advancing lutikizumab and Rinvoq in hidradenitis suppurativa, with multiple readouts expected throughout 2026 as the company pursues combination therapy strategies.

AbbVie Reports Record Sales and Earnings Beat, Advances Clinical Pipeline

Feb 12, 2026

AbbVie reported stronger-than-expected Q4 revenue of $16.62 billion and EPS of $2.71, beating consensus estimates. The company advanced a toxin-based therapy in Phase 2 trials and filed suit challenging Medicare drug-price negotiations for Botox.